Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.
CLDX Company Calendar
AUG. 8, 2024
Last Earnings
FEB. 23, 2025
Today
FEB. 24, 2025
Next Earnings (Estimated)
DEC. 31, 2025
Fiscal Year End
Recent Celldex Therapeutics News
Sat. February 22, 2025 1:25 AM EST | americanbankingnews.com
